Agilent Technologies (A) Citi Annual Global Healthcare Conference 2025 summary

Ignite transformation and operational changes

• Transitioned from a product-line, bottoms-up approach to an enterprise-wide decision-making model, emphasizing customer value and strategic pricing.

• Launched 10-12 enterprise projects, with organizational buy-in increasing as results became visible.

• Balanced quick wins with long-term investments, focusing on procurement, pricing, and regional manufacturing to drive top-line growth and margin improvement.

• Regionalized manufacturing footprint to mitigate tariffs and ensure production is close to major customer bases, making fundamental, lasting changes.

• Leveraged Ignite workstreams to quickly adapt to external challenges, such as tariffs and AI integration, enhancing agility and efficiency.

Financial outlook and guidance

• Provided 2026 revenue growth guidance of 4%-6%, with high-end assumptions based on pharma recovery and stable China revenues; low-end reflects continued biotech and academic/government pressure.

• Operating margin expected to improve by 60-75 basis points, with further upside possible if volume and pricing trends persist.

• China expected to remain flat at $300 million per quarter, with potential late-year stimulus upside not included in guidance.

• Specialty CDMO segment (NASD and BioVectra) is accretive to operating margins, with mid-teens growth expected and strong demand for advanced modalities.

• Tax rate increase attributed to Pillar Two regulations, with the rate closely aligned to cash tax and ongoing efforts to optimize.

Market and segment trends

• Pharma sector showing improved sentiment, especially among large caps, with increased M&A activity and budget normalization following tariff clarity.

• Replacement cycle for LC instruments in early stages, expected to drive 200-300 basis points of incremental growth; GC cycle is longer and smoother.

• China’s biotech sector benefits from government encouragement of advanced modalities, while applied markets remain subdued and academic/government funding is stimulus-dependent.

• GLP-1 business projected at $130 million in 2025, with growth driven by volume and new oral launches, benefiting both BioVectra and analytical tools.

• AI initiatives focus on customer-facing digital experiences and technical support, with Ignite providing a framework for enterprise-wide adoption.